Two recent publications focus on widely used treatments for other diseases to evaluate possible roles in the prevention of cancer. One looked at the potential of statins, a common heart disease drug, to prevent gynecologic cancers, and the other examined whether metformin, a drug for type 2 diabetes, could reduce the risk for breast cancer development.

Read the blog.

Thursday-Friday, September 28-29
9:30 a.m.-5:30 p.m. ET
Location: Virtual

This NIH workshop, Health and Aging Trajectories: Shared and Competing Risks and Resiliencies for Chronic Diseases Associated with Aging, will highlight state-of-the-art knowledge from various disciplines exploring potential shared and competing risks and resiliencies influencing aging processes and major diseases of aging, and essential molecular pathways and processes that may be harnessed for disease prevention, interception, and management. It will also increase public knowledge and awareness of chronic age-related diseases, their molecular and cellular mechanisms, shared and competing disease risks, and strategies to prevent disease outcomes.

Videocast
Day 1 https://videocast.nih.gov/watch=51101
Day 2 https://videocast.nih.gov/watch=51103

NCI invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics – specifically glucagon-like peptide (GLP)-1 or dual GLP-1/ glucose dependent insulinotropic polypepide (GIP)-1 receptor agonists (RAs) – impact cancer risk. These NOFOs seek to draw talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer.

PAR-23-279 (R01 Clinical Trial Optional)
PAR-23-280 (R21 Clinical Trial Not Allowed)

Expires: January 8, 2027

NOSI: Mechanisms Driving Obesity and Prostate Cancer Risk

NOT-CA-23-089

This NOSI encourages applications examining the mechanisms by which obesity drives aggressive prostate cancer risk. The biologic mechanisms driving both overall and aggressive prostate cancer risk are uncertain. Identifying differences in the mechanisms driving aggressive vs. overall (mostly non-aggressive) disease is critical to optimizing clinical care among men who develop prostate cancer.

Expires: September 8, 2024